Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BCMA
BCMA
Time for GSK to stop dreaming about Blenrep
EP Vantage
Mon, 11/7/22 - 10:53 am
GSK
BCMA
Blenrep
clinical trials
Multiple Myeloma
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Fierce Biotech
Fri, 08/5/22 - 10:42 am
Amgen
BCMA
PSMA
Multiple Myeloma
bispecific antibodies
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf
Fierce Biotech
Wed, 11/10/21 - 10:22 am
Poseida Therapeutics
CAR-T
BCMA
Takeda
AbbVie jumps on the BCMA train, opting into TeneoOne buy
Pharmaforum
Thu, 06/24/21 - 12:29 pm
AbbVie
TeneoOne
M&A
bispecific antibodies
BCMA
Pfizer halts BCMA trial amid safety woes, hit by DMD delay
Fierce Biotech
Tue, 05/4/21 - 10:53 am
Pfizer
BCMA
clinical trials
Duchenne Muscular Dystrophy
elranatamab
fordadistrogene movaparvovec
GSK nabs speedy review for one of its top prospects
Fierce Biotech
Tue, 01/21/20 - 11:46 am
GSK
FDA
priority review
BCMA
belantamab mafodotin
relapsed or refractory multiple myeloma
AbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoon
Pharmaforum
Thu, 11/21/19 - 10:39 am
AbbVie
Harpoon Therapeutics
R&D
BCMA
Multiple Myeloma
Eyeing a fast pitch for quick OK in race with bluebird, J&J/Legend team enjoys a regulatory embrace for their rival BCMA CAR-T
Endpoints
Thu, 04/4/19 - 11:53 am
JNJ
Legend Biotech
JNJ-68284528
CAR-T
BCMA
Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T
Endpoints
Sun, 01/6/19 - 01:58 pm
Poseida Therapeutics
IPOs
BCMA
CAR-T
Weekend ASH presentations hint at future of BCMA CARs
BioCentury
Tue, 12/4/18 - 09:39 am
ASH 2018
BCMA
CAR-T
Multiple Myeloma
GSK’s long-quiet cancer R&D group is ready to make some noise as it mounts a breakout late-stage effort
Endpoints
Wed, 01/10/18 - 10:15 am
GSK
R&D
cancer
GSK2857916
BCMA
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
Endpoints
Thu, 12/21/17 - 10:38 pm
JNJ
CAR-T
Legend Biotech
LCAR-B38M
BCMA
China
Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA
Endpoints
Thu, 08/10/17 - 11:37 am
IPOs
Sutro
Celgene
BCMA
Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?
Endpoints
Mon, 06/5/17 - 12:10 pm
Bluebird Bio
BCMA
CAR-T
Multiple Myeloma
ASCO 2017
bb2121
Celgene
Juno strikes deal to join bluebird, Novartis in busy multiple myeloma niche
Fierce Biotech
Sat, 08/6/16 - 01:19 pm
Juno Therapeutics
Bluebird Bio
Novartis
Multiple Myeloma
BCMA